The sales team for Purdue Pharma worked relentlessly to persuade doctors to prescribe OxyContin for pain relief
In a rebuttal to an opinion piece, Philip Machanick says while there is a distrust of Big Pharma and some medical bodies and research has been proven wrong, throwing out all of science and applying faulty arguments is not at all helpful
Paediatrician Alastair McApline says that the reasoning Angelo Ryan uses to justify this position in an M&G opinion piece is ‘specious and flawed’
Vaccines save lives. But why don’t we want to hear why people do not want to get the Covid-19 vaccine? It is important we get the right messaging across for us to achieve herd immunity.
Is Gates a superhero or a supervillain? That’s the wrong question. The right question is: How it is that one person can have so much influence over world health?
Government, according to Mkhize, is “relieved” as Pfizer eventually conceded and removed the “problematic term”
In mere months, Moderna transformed an old Polaroid factory in America into a state-of-the-art vaccine-production centre. Why can’t we do the same?
COMMENT: The AU has laid out a clear path for the continent to produce its own vaccines
Pfizer is accused of bullying Latin American governments by demanding they grant indemnity against potential civil claims relating to the vaccine
As India and South Africa push for relief at the World Trade Organisation through intellectual property rights waivers, India’s history of getting concessions may be the proverbial tripping block
There’s more than enough to be suspicious about with Big Pharma, but know your enemy
Cannabis is scheduled for its South African parole on September 18. Kelly McQue’s handy medical marijuana producers’ guide is an opening salvo against corporate medicine’s demand for exclusive rights to the plant’s healing powers
Big Pharma is already showing signs of putting revenue ahead of saving lives in the race to find a Covid-19 vaccine, according to experts
As Indian PM Narendra Modi visits South Africa, we must push to ensure continued access to affordable medicines.
Available data shows significantly higher investment by public and philanthropic institutions in TB research than by the pharmaceutical industry.
“We can use the technologies from other flaviviruses to get the product made by the end of 2016”